Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ZIM LABORATORIES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ZIM LABORATORIES Mar-23 |
ADCOCK INGRAM Jun-14 |
ZIM LABORATORIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 388 | 319 | - | |
Low | Rs | 67 | 230 | - | |
Sales per share (Unadj.) | Rs | 81.8 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 5.0 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 8.6 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 41.1 | 74.5 | - | |
Shares outstanding (eoy) | m | 48.73 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.8 | 2.9 | 96.2% | |
Avg P/E ratio | x | 45.4 | -11.5 | -395.5% | |
P/CF ratio (eoy) | x | 26.5 | -13.9 | -191.1% | |
Price / Book Value ratio | x | 5.5 | 3.7 | 150.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 11,096 | 46,340 | 23.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 493 | 2,908 | 17.0% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,985 | 16,016 | 24.9% | |
Other income | Rs m | 64 | 112 | 57.2% | |
Total revenues | Rs m | 4,049 | 16,128 | 25.1% | |
Gross profit | Rs m | 520 | -2,775 | -18.7% | |
Depreciation | Rs m | 175 | 691 | 25.3% | |
Interest | Rs m | 56 | 434 | 12.9% | |
Profit before tax | Rs m | 354 | -3,788 | -9.3% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 109 | 237 | 46.1% | |
Profit after tax | Rs m | 244 | -4,036 | -6.1% | |
Gross profit margin | % | 13.0 | -17.3 | -75.3% | |
Effective tax rate | % | 30.9 | -6.2 | -494.3% | |
Net profit margin | % | 6.1 | -25.2 | -24.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,909 | 11,730 | 16.3% | |
Current liabilities | Rs m | 1,108 | 6,600 | 16.8% | |
Net working cap to sales | % | 20.1 | 32.0 | 62.8% | |
Current ratio | x | 1.7 | 1.8 | 97.0% | |
Inventory Days | Days | 19 | 111 | 17.6% | |
Debtors Days | Days | 872 | 124 | 703.9% | |
Net fixed assets | Rs m | 1,569 | 6,838 | 22.9% | |
Share capital | Rs m | 487 | 74 | 655.3% | |
Net worth | Rs m | 2,003 | 12,571 | 15.9% | |
Long term debt | Rs m | 246 | 4,418 | 5.6% | |
Total assets | Rs m | 3,479 | 23,747 | 14.6% | |
Interest coverage | x | 7.3 | -7.7 | -94.9% | |
Debt to equity ratio | x | 0.1 | 0.4 | 35.0% | |
Sales to assets ratio | x | 1.1 | 0.7 | 169.9% | |
Return on assets | % | 8.6 | -15.2 | -56.9% | |
Return on equity | % | 12.2 | -32.1 | -38.0% | |
Return on capital | % | 18.2 | -19.8 | -91.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 375 | 1,367 | 27.4% | |
From Investments | Rs m | -362 | -420 | 86.2% | |
From Financial Activity | Rs m | 5 | 4,009 | 0.1% | |
Net Cashflow | Rs m | 30 | 4,957 | 0.6% |
Compare ZIM LABORATORIES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ZIM LABORATORIES With: BIOFIL CHEMICALS VINEET LABORATORIES TYCHE INDUSTRIES ALKEM LABORATORIES CORAL LAB.
It was indeed a volatile trading session for Indian share markets yesterday.